Literature DB >> 16249432

Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes.

Saul Genuth1, Wanjie Sun, Patricia Cleary, David R Sell, William Dahms, John Malone, William Sivitz, Vincent M Monnier.   

Abstract

Several mechanistic pathways linking hyperglycemia to diabetes complications, including glycation of proteins and formation of advanced glycation end products (AGEs), have been proposed. We investigated the hypothesis that skin collagen glycation and AGEs predict the risk of progression of microvascular disease. We measured glycation products in the skin collagen of 211 Diabetes Control and Complications Trial (DCCT) volunteers in 1992 who continued to be followed in the Epidemiology of Diabetes Interventions and Complications study for 10 years. We determined whether the earlier measurements of glycated collagen and AGE levels correlated with the risk of progression of retinopathy and nephropathy from the end of the DCCT to 10 years later. In multivariate analyses, the combination of furosine (glycated collagen) and carboxymethyllysine (CML) predicted the progression of retinopathy (chi2 = 59.4, P < 0.0001) and nephropathy (chi2 = 18.2, P = 0.0001), even after adjustment for mean HbA(1c) (A1C) (chi2 = 32.7, P < 0.0001 for retinopathy) and (chi2 = 12.8, P = 0.0016 for nephropathy). The predictive effect of A1C vanished after adjustment for furosine and CML (chi2 = 0.0002, P = 0.987 for retinopathy and chi2 = 0.0002, P = 0.964 for nephropathy). Furosine explained more of the variation in the 10-year progression of retinopathy and nephropathy than did CML. These results strengthen the role of glycation of proteins and AGE formation in the pathogenesis of retinopathy and nephropathy. Glycation and subsequent AGE formation may explain the risk of these complications associated with prior A1C and provide a rational basis for the phenomenon of "metabolic memory" in the pathogenesis of these diabetes complications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249432      PMCID: PMC2622724          DOI: 10.2337/diabetes.54.11.3103

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  48 in total

1.  Biochemistry and molecular cell biology of diabetic complications.

Authors:  M Brownlee
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

2.  ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.

Authors:  Jennifer L Wilkinson-Berka; Darren J Kelly; Suzanne M Koerner; Kassie Jaworski; Belinda Davis; Vicki Thallas; Mark E Cooper
Journal:  Diabetes       Date:  2002-11       Impact factor: 9.461

3.  Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.

Authors:  Josephine M Forbes; Mark E Cooper; Vicki Thallas; Wendy C Burns; Merlin C Thomas; Gail C Brammar; Fiona Lee; Sharon L Grant; Louise M Burrell; Louise A Burrell; George Jerums; Tanya M Osicka
Journal:  Diabetes       Date:  2002-11       Impact factor: 9.461

4.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

Authors:  Thorsten P Degenhardt; Nathan L Alderson; David D Arrington; Robert J Beattie; John M Basgen; Michael W Steffes; Suzanne R Thorpe; John W Baynes
Journal:  Kidney Int       Date:  2002-03       Impact factor: 10.612

5.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

6.  Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes.

Authors:  Ghislain Delpierre; François Collard; Juliette Fortpied; Emile Van Schaftingen
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

7.  High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control.

Authors:  James M Hempe; Ricardo Gomez; Robert J McCarter; Stuart A Chalew
Journal:  J Diabetes Complications       Date:  2002 Sep-Oct       Impact factor: 2.852

8.  Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy.

Authors:  S V McLennan; S K Y Martell; D K Yue
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

9.  The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.

Authors:  Alan Stitt; Thomas A Gardiner; Nathan L Alderson; Paul Canning; Norma Frizzell; Noel Duffy; Cliona Boyle; Andrzej S Januszewski; Mark Chachich; John W Baynes; Suzanne R Thorpe; Nathan L Anderson
Journal:  Diabetes       Date:  2002-09       Impact factor: 9.461

10.  Peroxynitrite induces formation of N( epsilon )-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite.

Authors:  Ryoji Nagai; Yuka Unno; Miki Cristina Hayashi; Shuichi Masuda; Fumitaka Hayase; Naohide Kinae; Seikoh Horiuchi
Journal:  Diabetes       Date:  2002-09       Impact factor: 9.461

View more
  147 in total

1.  Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy.

Authors:  M M Jack; J M Ryals; D E Wright
Journal:  Diabetologia       Date:  2011-06-03       Impact factor: 10.122

2.  Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes.

Authors:  Alejandra Planas; Olga Simó-Servat; Jordi Bañeras; Mónica Sánchez; Esther García; Ángel M Ortiz; Marisol Ruiz-Meana; Cristina Hernández; Ignacio Ferreira-González; Rafael Simó
Journal:  Acta Diabetol       Date:  2021-05-25       Impact factor: 4.280

3.  Plantar fascia thickness is longitudinally associated with retinopathy and renal dysfunction: a prospective study from adolescence to adulthood.

Authors:  Paul Z Benitez-Aguirre; Maria E Craig; Alicia J Jenkins; Patricia H Gallego; Janine Cusumano; Anthony C Duffin; Stephen Hing; Kim C Donaghue
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

Review 4.  Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?

Authors:  Aowen Zhuang; Josephine M Forbes
Journal:  Glycoconj J       Date:  2016-06-06       Impact factor: 2.916

Review 5.  Neuropathology of type 2 diabetes: a short review on insulin-related mechanisms.

Authors:  Elizabeth Guerrero-Berroa; James Schmeidler; Michal Schnaider Beeri
Journal:  Eur Neuropsychopharmacol       Date:  2014-01-30       Impact factor: 4.600

Review 6.  Mechanistic targeting of advanced glycation end-products in age-related diseases.

Authors:  Sheldon Rowan; Eloy Bejarano; Allen Taylor
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-29       Impact factor: 5.187

7.  Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.

Authors:  Helen Vlassara; Jaime Uribarri; Luigi Ferrucci; Weijing Cai; Massimo Torreggiani; James B Post; Feng Zheng; Gary E Striker
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

8.  Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study.

Authors:  B K Kilhovd; A Juutilainen; S Lehto; T Rönnemaa; P A Torjesen; K F Hanssen; M Laakso
Journal:  Diabetologia       Date:  2007-05-04       Impact factor: 10.122

Review 9.  Hyperglycemia and vascular metabolic memory: truth or fiction?

Authors:  Cristina Bianchi; Roberto Miccoli; Stefano Del Prato
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

10.  Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory.

Authors:  Pooi-See Chan; Mamta Kanwar; Renu A Kowluru
Journal:  J Diabetes Complications       Date:  2008-12-03       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.